Overview
Oncology Regulatory Landscape
The regulatory environment for oncology therapies involves specialized requirements from FDA Oncology Center of Excellence, EMA Committee for Medicinal Products for Human Use (CHMP), PMDA Oncology Review Division. This guide maps each requirement to ArcaScience's platform capabilities, demonstrating how AI-driven benefit-risk analysis aligns with and accelerates regulatory compliance.
Regulatory Requirements
Key Requirements by Agency
FDA Requirements
- ✓ Project Orbis for concurrent international oncology review
- ✓ Real-Time Oncology Review (RTOR) program requirements
- ✓ REMS with ETASU for oncology products
- ✓ Tumor-agnostic approval evidence standards
- ✓ Post-marketing requirements for accelerated approvals
EMA Requirements
- ✓ Conditional marketing authorization for oncology
- ✓ PRIME scheme eligibility and BRA requirements
- ✓ Oncology-specific PSUR/PBRER expectations
- ✓ Companion diagnostic co-development evidence
- ✓ Pediatric oncology investigation plan requirements
PMDA Requirements
- ✓ SAKIGAKE designation for oncology
- ✓ Japan-specific safety monitoring requirements
- ✓ Oncology conditional early approval pathway
- ✓ Post-marketing surveillance period requirements
ArcaScience Alignment
How ArcaScience Maps to Oncology Requirements
Data Coverage
Oncology-specific data from 47+ global sources, pre-harmonized and validated for regulatory submissions.
AI Models
Oncology-trained AI models for adverse event classification, signal detection, and benefit quantification with regulatory validation.
Regulatory Outputs
Pre-formatted outputs aligned with FDA Oncology Center of Excellence and EMA Committee for Medicinal Products for Human Use (CHMP) submission requirements.
Download
Get the Full Oncology Regulatory Landscape
Complete the form below to receive the document via email.
Related Resources